Welcome to the Dividing Cafe weekly market commentary focused on dividends in your portfolio and dividends in your understanding of economic life.

Hello and welcome to today's COVID and markets missive brought to you by the Dividing Cafe of the Bonson Group.

This is David Bonson. It's good to be back with you.

I feel like it's been a few days because yesterday we had our biweekly national video call.

So we use that as the podcast, about 45 minutes of COVID and markets discussion on Monday.

And then on Friday as our weekly dividend cafe and over the weekend we don't do a

COVID markets podcast and so really I haven't been able to record one of these since Thursday and

an awful lot has happened since then and really quite frankly an awful lot's happened in the last

10 minutes as I am sitting here to record.

First of all, just quickly, the market was up, 557 points today.

And yet, the thing I'm about to talk about is not at all related to that.

It did not come out until after the market closed.

And that is the early announcement,

stat news,

one of the big kind of medical news providers, that one of the leading companies in driving the vaccine development,

Moderna,

we've talked about it a lot at COVID markets, has said that

it's coronavirus vaccine trial produced robust immune response in all patients. Now, this was an

early stage human trial. The newly released data has just come out aftermarket, and it is in only 45 patients.

There's still placebo tests to do. There's still stage three clinicals, but it's incredibly

promising data to see neutralizing antibodies, the antibodies in all 45 patients in this early

stage human trial.

...